Korro Bio

Korro Bio is a biotechnology company pioneering a novel approach to drug discovery by leveraging endogenous RNA editing mechanisms. Founded in 2019 and headquartered in Cambridge, Massachusetts, the company aims to develop precision genetic medicines by making single-letter changes to RNA without permanently altering the genome. Its platform is built upon foundational research from the Broad Institute and Harvard University, focusing on ADAR-mediated editing to treat a wide range of diseases.

Company Overview

Korro Bio operates as a private biotechnology firm focused on creating a new class of genetic medicine. The company was launched with seed funding from notable venture capital firms including Atlas Venture and Newpath Partners. Its scientific approach is designed to harness the body's natural RNA editing machinery, specifically utilizing adenosine deaminase acting on RNA (ADAR) enzymes, to correct disease-causing mutations at the RNA level. This strategy aims to combine the reversibility of small molecule drugs with the precision of gene therapy, targeting conditions that have been difficult to address with conventional therapeutics.

Technology and Platform

The core technology is centered on ADAR-mediated RNA editing, which directs endogenous ADAR enzymes to make specific adenosine-to-inosine changes within messenger RNA (mRNA). This platform utilizes engineered guide RNAs (gRNAs) that bind to complementary target sequences and recruit natural ADAR proteins to edit specific adenosines. A key innovation involves optimizing these oligonucleotide guides for delivery, specificity, and efficiency. The company's research, leveraging insights from the Broad Institute, aims to overcome historical challenges in the field, such as off-target editing and efficient in vivo delivery, to create durable and tunable therapies.

Research and Development

Research and development efforts are directed toward advancing a pipeline of RNA editing therapeutics for both rare genetic disorders and more common diseases. Initial programs focus on targets in the liver and central nervous system, areas where oligonucleotide delivery has shown precedent. The company is investigating treatments for conditions like alpha-1 antitrypsin deficiency and certain neurodegenerative diseases. Preclinical work, often conducted in collaboration with academic partners like Harvard University, involves extensive validation in disease-relevant cellular and animal models to demonstrate proof-of-concept, editing efficiency, and therapeutic benefit before advancing candidates toward clinical trials.

Collaborations and Partnerships

Korro Bio has established strategic collaborations to accelerate its platform development and expand its therapeutic reach. A significant partnership was formed with Vertex Pharmaceuticals in 2021, focusing on discovering and developing RNA editing therapies for multiple targets. This collaboration provides Korro Bio with research funding and potential milestone payments. The company also maintains close ties with its academic founders at the Broad Institute and Harvard University, ensuring access to cutting-edge research in genomics and RNA biology. These alliances are critical for validating new targets and refining delivery technologies.

Leadership and Funding

The company is led by Chief Executive Officer Ram Aiyar, formerly of Atlas Venture, and co-founded by renowned scientists including David Liu of the Broad Institute. Its leadership team combines expertise in venture capital, drug development, and genome editing. Korro Bio has secured substantial venture funding from investors such as Atlas Venture, Newpath Partners, Surveyor Capital, and WuXi AppTec. In 2022, the company completed a significant Series B financing round, bringing its total capital raised to over $100 million to fund the progression of its lead programs toward human studies and expand its research platform.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Genetic engineering companies